A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

NCT01839214 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: VB-201 160mg
DRUG: Placebo

Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics